PLCB2 and renal cell carcinoma: To further validate whether the activation of the PI3K/AKT pathway is crucial for PLCB2-mediated EMT, we treated PLCB2 knockdown RCC cells with the PI3K/AKT pathway activator 740Y-P (20 μM).